Background The platinum-based chemotherapy drugs, cisplatin
S
urvival rates for childhood cancer are likely to increase over the next few decades. This growing population remains vulnerable to a variety of long-term, therapy-related sequelae as some anti-cancer drugs have adverse side effects that reduce their quality of life. 1 Platinum-based cheumotherapeutic agents such as cisplatin and carboplatin are widely used for the treatment of several pediatric solid tumors. 2 The treatment, however, often causes harmful, long-term side effects, such as nephrotoxicity, neuropathies, and ototoxicity. Platinum-induced ototoxicity usually manifests as a permanent, bilateral, high frequency, sensorineural hearing loss. Initially, hearing in the high frequency range is affected, progressing to the lower frequencies during later treatment. The incidence of hearing loss from cisplatin, a first generation platinum-based chemotherapy treatment, ranges from 26% to more than 90%. 3 Carboplatin is a second-generation platinum compound which is less toxic than cisplatin. Studies have reported 0-19% incidence of hearing loss from carboplatin. 4, 5 Several risk factors have been identified to predict hearing loss in children treated with platinum-based chemotherapy. 6 Children under 5 years of age tend to experience hearing loss. 7 High cumulative doses and cranial irradiation also cause hearing loss. [8] [9] [10] Other studies found that genetic factors and gender influence the incidence of ototoxicity. 6, 11 The aim of this study was to evaluate the prevalence and identify risk factors of hearing loss in children who received platinum-based chemotherapy.
Methods
A cross-sectional study was conducted from April to July 2012 in H. Adam Malik Hospital, Medan, North Sumatera Indonesia. Consecutive sampling was done on children who met the inclusion criteria, which were as follows: children aged 6 months -17 years with solid tumors who received at least two cycles of cisplatin or carboplatin, and the absence of recurrent ear infections. Subjects who had a history of hearing impairment before therapy, had undergone radiotherapy of the head, or had tumors in the central nervous system, were excluded. All children which their parents approve to informed concern were evaluated by an audiologist using Oto Read®, a portable otoacoustic emissions (OAE) screener, made by Interacoustics A/S Assens, Denmark 2003. This equipment has 86.4% sensitivity and 99.4% specificity.
This study was approved by the Medical Ethics Committee of the University of North Sumatera Medical School.
Possible associations between hearing loss and risk factors were analyzed by Chi-square and Fisher's exact tests. A value of P < 0.05 was accepted to be statistically significant. Data were analyzed using SPSS version 15.
Results
Of 24 children who had received platinum-based chemotherapy, 2 children excluded from the study because of recurrent ear infections. The 22 children who met the inclusion criteria consisted of 11 children who received cisplatin and 11 children who received carboplatin.
The largest group of subjects by age was the <5-year-old group (11/22) . Retinoblastoma was the most common type of tumour (15/22) followed by nasopharyngeal carcinoma (2/22), osteosarcoma (2/22), hepatoblastoma (1/22), fibrosarcoma (1/22), and ovarian cancer (1/22) ( Table 1) . None of the patients received additional ototoxic drugs, such as certain antibiotics or diuretics. None of the children or parents reported subjective hearing loss before the chemotherapeutic treatment.
Of 7 subjects with hearing loss, 5 had received cisplatin and 2 had received carboplatin. However, Fisher's exact test revealed no significant association between the chemotherapy used and hearing loss (P=0.361). Hearing loss was most commonly found in the < 5 years age group of children (5/7). However, Chi-square test revealed no significant differences between age groups as they related to hearing loss (P=0.35). Nor was there a significant relationship between gender and the occurrence of hearing loss (P=0.652), as shown in Table 2 . We analyzed 10 males and 12 females, but found no relationship between gender and hearing loss. The result differed from that of a previous study which showed that males were more susceptible to cisplatin-associated hearing loss by as much as 4 times more than females. Since they could not elucidate the reason, they suggested that the difference was due to genetic factors. 6 In 2004, a study found that children < 5 years of age at the time of treatment were 21 times more likely to have hearing loss than patients aged 15-20 years. 7 Another study showed that children aged < 12 years were at higher risk compared to those aged > 12 years. 15 Most of our subjects (11/22) were children under 5 years of age. Five out of 7 children who had hearing loss in this study was under 5 year-age group, but no significant difference in hearing loss was observed between age groups (P=0.35).
The cumulative cisplatin dose is considered to be the main risk factor for hearing loss. A German study found 12% hearing loss appeared at a dose range of 1-200 mg/m 2 . 8 Other studies have reported that wide ranges of cisplatin doses (120-450 mg/m 2 ) were correlated with a progressive risk of developing severe hearing loss. 13, 15, 16 Carboplatin, at the standard dose, does not appear to be a significant risk factor for hearing loss. 13 A Netherlands study showed that of 25 children treated with carboplatin, none had hearing loss afterwards, while a Washington study showed that only 4% of children who received carboplatin had hearing loss. 4, 17 Although ototoxicity might be lower, high doses (total dose 2 g/m 2 ) of carboplatin may cause high and low frequency hearing loss. 18 In an animal study, carboplatin damaged inner hair cells at a low dose and outer hair cells at a high dose. 19 In our study, we divided cisplatin into three dosage groups. Subjects who received cumulative doses above 600 mg/m 2 had the highest prevalence of hearing loss. We found only 1 patient with hearing loss who received a cisplatin dose in the range of 200 to 400 mg/m 2 and 4 patients with hearing loss who received >600 mg/m 2 cisplatin. The one patient with hearing loss in the 200 to 400 mg/m 2 group was a teenager diagnosed with carcinoma of the ovary. She often listened to music using headphones at a With regards to cumulative doses, both cisplatin and carboplatin regimens had significant relationships between higher cumulative dose and hearing loss (P=0.022 and P=0.004, respectively), as shown in Table 3 .
Discussion
A 1983 study in nine children found an 88% rate of hearing loss at high frequencies after treatment with cisplatin. 12 Another study reported hearing loss in 37% of children treated with cisplatin. 13 The first study on carboplatin in children was conducted in 1990 and found that 19% suffered hearing loss. 14 However, another study in the Netherlands in 2005 found that no hearing loss was detected in children after carboplatin administration. 4 In our study, 7 out of 22 patients had hearing loss after using platinum- 19, 20 Platinum agents target the DNA of proliferating cells to exert tumoricidal effects. 21 In contrast to tumor cells, cochlear cells proliferate slowly, and mammalian cochlear cells not at all. 22 As such, permanent and bilateral hearing loss may result. A study revealed that no improvement was observed with time. Instead, worsening or progression of hearing loss in the lower frequencies was detected during follow-up. 13 We found that 7 patients had bilateral hearing loss. We did not assess for a worsening or permanent effect of platinum-based chemotherapy on hearing loss, as this study had a cross-sectional design. Further longitudinal studies with a large sample size is needed to investigate this effect.
Hearing loss can be detected by audiometry, OAE and brainstem-evoked response audiometry. Otoacoustic emission directly assesses the function of hair cells. The OAE can be used as a screening test for ototoxicity, but does not determine the threshold of hearing as well as audiometry. 23 Most subjects were <5 years of age which is an obstacle for audiometric examinations, as it is difficult for these patients to cooperate with the examiner.
In a previous study, hearing loss in children affected their speech, language, educational and social-emotional development. Auditory capability for children aged <5 years is very important because at this age children learn language. High frequency hearing loss impacts their academic achievement. 24, 25 A US study involving 1,228 subjects with minimal sensorineural hearing loss showed hearing difficulty in educational test compared to normal children. 26 In our study, most patients were < 5 years of age and had not attended school, but we received two reports from parents that their children had difficulty hearing in crowded areas. Two subjects with hearing loss were in school-aged. One subject stopped attending school due to financial problems, while the other attended school and continued the chemotherapy protocol. This latter patient was able to attend school, participate in academic activities, and had no difficulty in communication. We recommended that she undergo regular hearing exams, since she would complete the chemotherapy protocol later, as additional treatments would affect the cumulative dose.
A limitation of the study was that we did not perform OAE examinations prior to chemotherapy administration, so we could not compare subjects' initial auditory function to that after chemotherapy. Other limitations were the small sample size and lack of long-term monitoring for the possibility of permanent hearing loss.
In conclusion, hearing loss is common in children with solid tumors who receive platinumbased chemotherapy. Higher cumulative doses of platinum-based chemotherapy are a risk factor for hearing loss.
